by The Sulfasalazine market is in trends due to increasing prevalence of rheumatoid arthritis and inflammatory bowel diseases. Sulfasalazine is an anti-inflammatory drug used for the treatment of rheumatoid arthritis and inflammatory bowel diseases like ulcerative colitis. It consists of two substances – sulfapyridine linked to 5-aminosalicylic acid. Sulfasalazine works by blocking the production of prostaglandins and leukotrienes which are chemicals that cause inflammation and pain.
The global Sulfasalazine market is estimated to be valued at US$ 2.32 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Sulfasalazine is one of the most commonly prescribed medications for rheumatoid arthritis and ulcerative colitis due to its effectiveness and low cost. The prevalence of these conditions is rising globally due to sedentary lifestyles and changing demographics which is driving the demand for sulfasalazine.
Key Takeaways
Key players operating in the Sulfasalazine market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc.
The Sulfasalazine Market Trends prevalence of rheumatoid arthritis and inflammatory bowel diseases is fueling the demand for sulfasalazine globally. As per estimates, over 1.3 million Americans suffer from rheumatoid arthritis while ulcerative colitis has a global prevalence of 0.5-24.5 cases per 100,000 persons.
The manufacturers are expanding their operations in emerging markets of Asia Pacific and Latin America owing to the large patient pools suffering from arthritis and colitis. Furthermore, these regions are witnessing rising healthcare expenditures and improved access to diagnosis and treatment, which is boosting the Sulfasalazine Market.
Market Key Trends
The increasing awareness about inflammatory conditions and their treatment options through various social media campaigns and patient support organizations is driving the s Sulfasalazine Market Size and Trends. Additionally, various new drug delivery methods for sulfasalazine like transdermal patches and sustained release formulations are being researched to improve patient compliance. Companies are also developing combination therapies of sulfasalazine with other medications to enhance efficacy in Treatment Resistant Ulcerative Colitis (TRUC) cases. Furthermore, with rising geriatric population prone to arthritis, the demand for generic and affordable treatment options like sulfasalazine is projected to grow substantially in the coming years.
Porter’s Analysis
Threat of new entrants: The sulfasalazine market has moderate threat due to presence of established brands and high capital requirement for R&D and manufacturing. Bargaining power of buyers: Buyers have moderate to high bargaining power due to availability of generics and branded options for sulfasalazine treatment. Bargaining power of suppliers: Suppliers have low to moderate bargaining power as raw materials for sulfasalazine are commodity and suppliers are fragmented. Threat of new substitutes: Threat of substitutes is low as sulfasalazine is effective for treatment of ulcerative colitis and rheumatoid arthritis with few side effects. Competitive rivalry: The market has high competitive rivalry due to presence of many established generic and branded players.
Geographical Regions
North America accounts for largest share in sulfasalazine market value owing to high awareness, healthcare expenditure and growing incidences of rheumatoid arthritis and ulcerative colitis. Asia Pacific is fastest growing region driven by factors like increasing healthcare spending, rising medical tourism and rapidly aging population. Countries like India, China and Japan are major contributors to the Asia Pacific sulfasalazine market growth.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
About Author - Ravina Pandya
Ravina Pandya,a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile
